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Abstract
Background: Granulosa cell tumors (GCT) of the ovary often express aromatase and synthesize estrogen, which in turn may
influence their progression. Recently a specific point mutation (C134W) in the FOXL2 protein was identified in .94% of
adult-type GCT and it is likely to contribute to their development. A number of genes are known to be regulated by FOXL2,
including aromatase/CYP19A1, but it is unclear which are direct targets and whether the C134W mutation alters their
regulation. Recently, it has been reported that FOXL2 forms a complex with steroidogenic factor 1 (SF-1) which is a known
regulator of aromatase in granulosa cells.
Methodology/Principal Findings: In this work, the human GCT-derived cell lines KGN and COV434 were heterozygous and
wildtype for the FOXL2:C134W mutation, respectively. KGN had abundant FOXL2 mRNA expression but it was not expressed
in COV434. Expression of exogenous FOXL2:C134W in COV434 cells induced higher expression of a luciferase reporter for
the ovarian specific aromatase promoter, promoter II (PII) (2516bp) than expression of wildtype FOXL2, but did not alter
induction of a similar reporter for the steroidogenic acute regulatory protein (StAR) promoter (21300bp). Co-
immunoprecipitation confirmed that FOXL2 bound SF-1 and that it also bound its homologue, liver receptor homologue
1 (LRH-1), however, the C134W mutation did not alter these interactions or induce a selective binding of the proteins. A
highly conserved putative binding site for FOXL2 was identified in PII. FOXL2 was demonstrated to bind the site by
electrophoretic mobility shift assays (EMSA) and site-directed mutagenesis of this element blocked its differential induction
by wildtype FOXL2 and FOXL2:C134W.
Conclusions/Significance: These findings suggest that aromatase is a direct target of FOXL2:C134W in adult-type GCT via a
single distinctive and highly conserved binding site in PII and therefore provide insight into the pathogenic mechanism of
this mutation.
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Introduction
The forkhead transcription factor FOXL2 has recently emerged
as a critical regulator of ovarian function. It is one of the first
molecular markers of ovarian development [1] and its ablation
inhibits ovarian differentiation of the embryonic bipotential gonad
[2,3,4,5]. It is one of a handful of genes that is mutated in
premature ovarian failure (POF) and recently, a specific somatic
mutation in FOXL2 (C134W) was discovered in more than 94%
of ovarian adult-type GCT [6,7]. The mutation is likely to
facilitate adult-type GCT development and may possibly be the
tumor’s primary cause.
Despite the biological importance of FOXL2, many details of its
action remain unknown or are the subject of conflicting reports. A
number of putative target genes for FOXL2 have been identified
including genes involved in steroidogenesis (e.g. STAR, CYP17 and
aromatase), inflammation (e.g. NFAT and PTGS2/COX2) and
apoptosis or detoxification (e.g. MNSOD) [8,9]. Interestingly,
aromatase was found to be up-regulated by FOXL2 in COS7 cells
and ovine granulosa cells [10] but down-regulated by FOXL2 in
CHO cells [11]. FOXL2 has been reported as a negative regulator
of the STAR gene [12], therefore it is likely that the consequence of
its binding to gene promoters is context or co-factor dependent.
The influence of the FOXL2:C134W mutation on the regulation
of these genes is unknown.
The DNA binding site of FOXL2 is also controversial. Some
reports claim that it binds sites similar to the consensus forkhead
element [13,14], while another study suggests that it binds a
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(TCAAGGTCA) also known as the SF-1 response element (SFRE)
[15]. These findings are intriguing because forkhead factors are
known to serve as co-regulators of nuclear receptors and recently,
FOXL2 was reported to bind and co-regulate SF-1 via its forkhead
domain [14,16].
The molecular consequence of the FOXL2:C134W mutation is
also unclear. C134 is located within wing 2 of the forkhead
domain, which is a divergent component of the domain’s
secondary structure and of uncertain function. Although the
forkhead domain as a whole has DNA binding function, it is
unclear whether wing 2 contributes to DNA binding [17,18,19,20]
or facilitates other molecular interactions [7,21]. Importantly, a
recently published characterization of the FOXL2:C134W
mutation has suggested that it does not markedly alter the
regulation of a number of known FOXL2 target regions [22].
In this work, we have characterized the two GCT cell lines,
KGN and COV434, with respect to FOXL2 mutation status and
expression of aromatase and SF-1. We report that the mutation
alters FOXL2 regulation of the aromatase promoter but not that
of the StAR promoter. We provide evidence that the effect of the
mutation on aromatase regulation is not altered by the presence of
SF-1 and show that it does not alter interactions between FOXL2
and SF-1 or its close homologue, LRH-1. We identify a highly
conserved forkhead element in the aromatase promoter which is
bound by FOXL2 and finally, we demonstrate that this site alone
confers its sensitivity to FOXL2:C134W.
Results
KGN cells have robust expression of aromatase mRNA
and the FOXL2:C134W mutation; COV434 cells have little
aromatase mRNA expression, are wildtype for FOXL2, but
do not express it
Two well-characterized GCT cell lines, KGN and COV434,
have been the subject of a number of comparative studies due to
their contrasting characteristics [23,24,25,26]. The KGN cells
have a spindle-like morphology and form a monolayer at
confluence [27] whereas the COV434 cells are spherical, grow
in clusters and their growth is inhibited by cell-cell contact [28,29].
The KGN cells are known to harbor FOXL2:C134W [30]. We
sought to establish the FOXL2 genotype of the COV434 cell line
and characterize the mRNA expression of aromatase and its
known regulator SF-1 in both cell lines.
Direct sequencing of genomic DNA confirmed that the KGN
cells were heterozygous for FOXL2:C134W but revealed that the
COV434 cells had wildtype sequence (data not shown). However,
reverse transcribed-quantitative PCR (RT-qPCR) analysis of the
FOXL2 transcript showed that where the KGN had robust
FOXL2 mRNA expression, the COV434 cells had little or no
FOXL2 expression (Fig. 1A).
In normal granulosa cells, aromatase is known to be up-
regulated by follicle stimulating hormone (FSH) signaling via
cAMP and in cooperation with the protein kinase C (PKC)
pathway. Aromatase and SF-1 expression were measured by RT-
qPCR in KGN and COV434 cells, following separate and
combined treatment with forskolin (FSK) and phorbol myristate
acetate (PMA) (Fig. 1B and 1C). Strikingly, KGN cells had robust
expression of aromatase mRNA upon FSK treatment which was
increased by combined treatment with PMA, whereas in the
COV434 cell line, aromatase mRNA expression was either very
low or absent (Fig. 1B). SF-1 mRNA expression had greater
variance and the difference in expression between the lines was not
significant (Fig. 1C).
C134W augments FOXL2 induction of aromatase but not
StAR
The finding that COV434 cells do not express FOXL2
provided the opportunity to examine the influence of ectopic
FOXL2 expression on the regulation of a firefly luciferase reporter
for the ovarian specific promoter of aromatase, PII (PII 2516bp-
luciferase) [31]. We expressed FOXL2 and FOXL2:C134W
together with PII 2516bp-luciferase in COV434 cells. The
FOXL2 and FOXL2:C134W expression constructs were equally
expressed in COV434 cells (Fig. S1) and both up-regulated
aromatase reporter expression with FOXL2:C134W stimulating
twice as much expression as the wildtype protein (Fig. 2A). In
parallel, we tested the influence of the mutation on the regulation
of a firefly luciferase reporter for the StAR promoter (StAR
21300bp-luciferase) [32], as StAR was previously reported to be
down-regulated by FOXL2 [12]. Interestingly, FOXL2 expression
up-regulated StAR reporter expression contrary to the previous
report, but there was no difference in the stimulation by FOXL2
and FOXL2:C134W (Fig. 2B). These data therefore suggest that
the FOXL2 mutation alters aromatase stimulation but not that of
StAR. Given the unexpected result for StAR, we repeated the
experiment in COS7 cells and found that in that setting, FOXL2
down-regulated StAR reporter expression as previously reported
(Fig. 2C). Aromatase was differentially regulated by FOXL2 and
FOXL2:C134W in COS7 cells, as seen in the COV434 cells, but
was more sensitive to SF-1 expression (Fig. 2D). In summary, these
results suggest that the C134W mutation increases stimulation of
aromatase by FOXL2 in GCT, but does not alter its regulation of
StAR.
FOXL2 binds SF-1 and inhibits its transcriptional
activation, and it also binds LRH-1, but these interactions
are not altered by C134W
Given that the SF-1 and LRH-1 proteins are key regulators of
aromatase [33,34] and it has been reported that SF-1 forms a
physical complex with FOXL2 [14,16], we tested whether human
FOXL2 could also form a complex with human LRH-1, whether
the mutation prevented interactions between FOXL2 and SF-1 or
LRH-1, or whether it conferred preferential binding to one of
them. Human SF-1 was clearly pulled down by immunoprecip-
itation of both wildtype FOXL2 as reported and also mutant
FOXL2 (Fig. 3A). LRH-1 was pulled down in a similar manner to
SF-1 by FOXL2 immunoprecipitation and again this was not
affected by the C134W mutation (Fig. 3B). Finally, co-expression
of both SF-1 and LRH-1 with FOXL2 and FOXL2:C134W did
not result in an altered binding or preferential binding of the co-
factors to the FOXL2 proteins (Fig. 3B). These findings together
confirm that FOXL2 binds SF-1 and show that it also binds its
homologue LRH-1, but suggest that the manner in which it does
so is not affected by the presence of the C134W mutation.
A highly conserved putative forkhead element resides in
the ovarian aromatase promoter
The nature and context of DNA binding sites of transcription
factors give insight into the action of those transcription factors.
We sought to determine where in PII, FOXL2 bound to regulate
the promoter. FOXL2 is a highly conserved protein [35] with a
fundamental role in ovarian development and this suggests that
significant target sites may also be conserved. We performed in
parallel, inter-species conservation analysis of the promoter and
mapping of binding sites for known transcription factors (Fig. 4).
Five highly conserved sequences were identified, of which one
contained a putative forkhead element (282 to 269). The other
FOXL2:C134W and Aromatase
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previously described binding site for dimeric GATA transcription
factors (2179 to 2165) [36,37] and an uncharacterized putative
SFRE (2193 to 2184). Two further putative forkhead elements
were present in the promoter, but these did not reside within
conserved regions. We selected the highly conserved putative
forkhead element for further study.
FOXL2 binds to the putative forkhead element in the
aromatase promoter and disruption of the element
blocks increased stimulation by FOXL2:C134W
To determine whether the identified putative forkhead binding
element in PII was bound by FOXL2 we performed an EMSA
using 38bp probes centered on the site (Fig. 5A). We generated a
mutant probe in which the three consecutive thymidine bases
characteristic of the forkhead element core sequence (refer to
Fig. 6) were changed to three guanines. Both the wildtype FOXL2
and FOXL2:C134W proteins bound the wildtype DNA probe
robustly and bound the mutated probe at a reduced level (Fig. 5A
and Fig. S2). The addition of FLAG antibody to a binding reaction
of wildtype FOXL2 with wildtype probe generated a supershifted
band confirming that the detected complexes included the FOXL2
protein (Fig. 5A, lane 7). These data suggest therefore that the
identified element is bound by FOXL2 and that both the wildtype
and mutant proteins bind it in a similar manner. Interestingly, a
minor band positioned above the major complex band appeared
to have more intensity in the FOXL2:C134W lane (Fig. 5A, lane
5) and this may indicate that the mutation was promoting the
formation of a higher order complex for a small portion of the
protein.
To test whether the identified forkhead element was a functional
regulator of the promoter and whether it could explain the
increased stimulation of PII 2516bp-luciferase by the
FOXL2:C134W (Fig. 2) we generated a mutant version of the
reporter, in which the putative element was mutated in the same
Figure 1. The KGN and COV434 cell lines differ in expression of FOXL2 and aromatase mRNA.(A) RT-qPCR measures of FOXL2 mRNA in
KGN (heterozygous for FOXL2:C134W) and COV434 cells (wildtype) relative to expression of 18s rRNA, N. D.: not detected. Mean of three experiments,
error bars: 6SEM. (B) RT-qPCR measures of mRNA expression for aromatase following 24hr treatment with separate and combined FSK and PMA, F:
FSK, P: PMA. Means of three experiments, error bars: 6SEM, differences in expression were tested by 1-way ANOVA followed by Dunnett’s post hoc
analysis, relative to the untreated control for each cell line. Indications of significance are a.=p,0.05, b.=p,0.01 and c.=p,0.001. (C) RT-qPCR
measures of mRNA expression for SF-1 within the cDNA set generated for panel B. Differences in expression between the two cell lines and the
combined treatments were tested by 2-way ANOVA followed by Tukey’s post hoc analysis considering all possible comparisons. No comparison was
significantly different (difference between cell lines p,0.097).
doi:10.1371/journal.pone.0014389.g001
FOXL2:C134W and Aromatase
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FOXL2:C134W was expressed with the reporters, differential
expression was detected with the wildtype reporter but not with
the mutated reporter (Fig. 5B). These data therefore indicate that
this element is required for the increased stimulation of the
wildtype reporter by FOXL2:C134W. Importantly, the mutant
and wildtype aromatase reporters were equally stimulated by
FSK/PMA treatment (Fig. 5B) indicating that the mutant
promoter was still functional and regulated in a normal fashion
by other regulatory elements within the promoter (e.g. cAMP
response elements).
Discussion
The potentially oncogenic FOXL2:C134W mutation is remark-
able for its molecular specificity and therefore it provides an
opportunity to define a new pathogenic mechanism. Here we
confirmed that the KGN cell line is heterozygous for the
FOXL2:C134W mutation and found that it has robust FOXL2
expression. The COV434 cell line was wildtype for FOXL2 but
had low or no expression. FSK/PMA treatment induced
aromatase robustly in KGN cells but not in COV434 cells. These
findings combined with a dramatic difference in cellular
morphology [27,29] show that the KGN and COV434 differ
greatly in their biology and they of course suggest that COV434
were not derived from an adult-type GCT but more likely from a
rarer juvenile-type GCT. In support of this, the KGN cells had
been generated from a 73 year old patient [27] and the COV434
cells were taken from a 27 year old [28,29]. Significantly, the
finding that COV434 cells lack FOXL2 together with reports by
Kalfa and co-workers, that juvenile-type GCT have low or
aberrant FOXL2 expression [38,39] suggest that an alteration of
FOXL2 function is a feature of both the adult and juvenile GCT
subtypes.
The FOXL2:C134W mutation was found to increase FOXL2
induction of an aromatase reporter but not one for StAR,
Figure 2. The C134W mutation increases FOXL2 stimulation of aromatase but does not alter FOXL2 regulation of StAR. Luciferase
assays were performed in COV434 and COS7 cells with PII 2516bp-luciferase and StAR 21300bp-luciferase 48hr after co-transfections with FOXL2:wt
(wt), FOXL2:C134W (m), SF-1 and pcDNA3.1+ (2) as indicated, and either treated (grey bars) or untreated (white bars) with combined FSK and PMA.
(A) Aromatase reporter in COV434 cells. (B) StAR reporter in COV434. (C) StAR reporter in COS7 cells. (D) Aromatase reporter in COS7 cells. Means of
four (COV434) or three (COS7) experiments, error bars: 6SEM, differences in expression were tested by 1-way ANOVA followed by Tukey’s post-hoc
analysis considering all possible comparisons, indications of significance are a.=p,0.05, b.=p,0.01 and c.=p,0.001, and they relate to
comparisons of FOXL2 transfections with the closest matched pcDNA3.1+ control or when indicated with braces, to differences between matched
FOXL2:wt and FOXL2:C134W transfections. Differences between SF-1 transfection alone and matched pcDNA3.1+ controls were not significant for all
panels.
doi:10.1371/journal.pone.0014389.g002
FOXL2:C134W and Aromatase
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promoters is different and that aromatase may belong to an
undefined subset of genes that are influenced by the mutant
protein. Notably, the mutation appeared to circumvent the
requirement for FOXL2 stimulation of aromatase on concurrent
PKA and PKC signaling (Fig. 2A). The StAR promoter was
previously reported to be negatively regulated by FOXL2 and we
confirmed that this occurred in the non-GCT cell line, COS7.
These findings mean that FOXL2 action is both promoter and cell
type specific and implies that FOXL2 interacts with multiple co-
regulatory factors that result in either stimulation or repression of
its target genes.
Few co-regulators have been described for FOXL2. It has been
reported to form complexes with SMAD3 [21], DPC103/
GEMIN3 [40], ERa [41] and SF-1 [14,16], and to be subject to
sumoylation by Ubc9 [42,43]. One or all of these interactions
could be relevant to the regulation of aromatase in various settings,
but in the ovary the relationship between FOXL2 and SF-1 and its
close homologue LRH-1, are of clear importance and have
relevance to concurrent PKA and PKC signaling [33,34]. A
number of results presented here however, argue against the
interaction of FOXL2 with SF-1 or its homologue LRH-1 being
involved in the pathogenicity of FOXL2:C134W. First, the co-
immunoprecipitation of SF-1 or LRH-1 with FOXL2 was not
altered by the presence of the mutation (Fig. 3). It is possible that a
more subtle affect may be detected with a more sensitive method
(e.g. Biacore) but it is unclear that such would explain the
pathological impact of the substitution. Second, our luciferase
assays demonstrated that SF-1 increased reporter expression
cooperatively and to the same extent when combined with either
wildtype or mutant FOXL2 (Fig. 2 and 5) and this happened with
both the aromatase and StAR reporters (Fig. 2). Interestingly, in
COV434 cells, FOXL2 did not stimulate the StAR promoter
without SF-1 being co-transfected suggesting that its stimulatory
action here was entirely dependent on SF-1 (Fig. 2B). Thirdly,
when the putative forkhead site in PII, which conferred its
sensitivity to FOXL2:C134W, was disrupted in the reporter, SF-1
still stimulated it to the same extent as the wildtype reporter and
did so in cooperation with either the mutant or wildtype FOXL2
(Fig. 5B). We conclude therefore, that it is unlikely that the
pathogenicity of FOXL2:C134W relates to an alteration of its
binding of SF-1 or, with less certainty, LRH-1.
The sequence and context of DNA elements bound by
transcription factors give insight into the action of those factors.
Here we identified a highly conserved region in PII containing a
forkhead element that conferred its sensitivity to increased
stimulation by FOXL2:C134W (Fig. 4 and 5). Our approach
was validated by the co-identification of both the gene’s TATA
box and a previously characterized dimeric GATA binding site
stretching from 2179 to 2165 [37]. The high conservation of the
element, extending to lizards and frogs (Fig. 4), suggests that it may
be of fundamental importance in the regulation of aromatase by
Figure 3. FOXL2 binds SF-1 and also LRH-1, but these interactions are not altered by the C134W mutation. Co-immunoprecipitation
was performed for SF-1 and LRH-1 via FLAG-tagged FOXL2:wt and FOXL2:C134W (m) 24hr following co-transfection into COV434 cells, as indicated.
(A) SF-1 alone. The use of the same antibody across more than one blot is indicated by a vertical bar. Two arrows are used to indicate SF-1 because
this antibody typically detects two bands for SF-1 which is thought to result from post-translational modification of the protein. (B) SF-1 and LRH-1
alone and combined. Black arrows indicate proteins detected by antibody, green arrows indicate non-specific bands.
doi:10.1371/journal.pone.0014389.g003
FOXL2:C134W and Aromatase
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ovarian differentiation, its action via this element may be crucial to
female gonadal development. As we hoped, a number of features
of the identified element illuminate the role of FOXL2 in the
regulation of aromatase.
The first observation we have made is that the conserved region
extends well beyond the forkhead element it contains. Strikingly,
the region is of a similar length to a putative FOXL2 binding site
recently identified by Corpuz and co-workers in the promoter of
the FSHb subunit gene (FSHB) (Fig. 6) [44]. In their study,
sequential mutational analysis revealed that FOXL2 binding was
reduced by mutation of any of the 12 consecutive base pairs at
their site. Our conserved region is 14bp long and has high
sequence similarity to their sequence (Fig. 6) and importantly, both
sites include a run of four thymidines instead of the normal three
found in the consensus forkhead binding sequence [45]. Our study
therefore, appears to corroborate Copuz’ finding that FOXL2
binds this sequence motif and implies that the pathogenicity of
FOXL2:C134W may relate to sequences like these.
A second observation we have made of our identified element is
that it is also a putative insulin response sequence (IRS), which as a
group have the consensus T(G/A)TTT(T/G)(G/T) [46] (Fig. 6).
This is highly significant as IRS are well documented to be bound
by members of the FOXO subfamily of forkhead proteins
[47,48,49] and members of this family play a key role in the
regulation of ovarian follicle development [50]. For example, the
Foxo3 knockout mouse has a POF phenotype not dissimilar to the
Foxl2 knockout [51,52]. Hence, it possible that the action of
FOXL2 on the aromatase promoter is integrated with that of the
FOXO proteins via this element.
A third observation is that the identified forkhead element is
immediately flanked by a potential binding site for members of the
doublesex and mab-3 related transcription factor (DMRT) family so
that the core sequence of this binding site (A/T,TGT) [53] is
contained within the highly conserved 14bp region (Fig. 6). This is of
significance, because the DMRT proteins are homologues of the
Drosophilagenethatcontrolssexdeterminationinthatspecies[54].In
mammals, DMRT1 is a key positive regulator of testis development
[55] and other members of the DMRT family also exhibit male
specific expression [56,57]. It is possible therefore that the identified
sequence is not only key to female gonadal development but is
regulated in both female and male sex determination.
Figure 4. A highly conserved putative forkhead element resides in the ovarian aromatase promoter (PII). Sequence conservation
analysis was performed on the human aromatase promoter (2516bp) and a highly conserved putative FOXL2 binding site was identified. (I.) PhyloP
conservation analysis of 32 placental mammals. Scores exceeding 3 or 20.5 are truncated and indicated in pink. Conserved sequences containing at
least 4 contiguous base pairs with phyloP scores .2 were selected (numbered 1–5). The conserved sequences and putative or known regulatory
elements within them are displayed to the right. A well described but less conserved functional SFRE is also indicated (S.) [34]. (II.) Multiz alignment
based on 46 vertebrates demonstrating high conservation of the putative FOXL2 binding site. Species displayed: a. monkey (Rhesus), b. mouse, c.
dolphin, d. dog, e. possum, f. chicken, g. lizard, h. frog. Light blue bar indicates limit of available sequence for frog.
doi:10.1371/journal.pone.0014389.g004
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sequence is that it is actually a forkhead sequence and not a
binding site for members of a different protein family. FOXL2
forms complexes with other transcription factors (e.g. SF-1) and it
is likely to bind DNA both directly and indirectly (this is probably
why Benayoun and co-workers found that FOXL2 bound an
approximate SFRE [15]). This means that the FOXL2:C134W
mutation, which resides within the DNA binding domain of
FOXL2, is likely to confer its pathogenic effect while that domain
is directly bound to DNA, and therefore it is either directly altering
DNA binding or it is altering an associated protein-protein
interaction. Critically, we saw no evidence that the mutation
directly alters DNA binding in our EMSA blots (Fig. 5A and Fig.
S2). With this in mind a model can be proposed for the action of
FOXL2:C134W on the aromatase and StAR promoters (Fig. 7).
On the aromatase promoter, FOXL2 binds directly to DNA at the
identified forkhead site and the mutation alters a relevant protein-
protein interaction (relevant to concurrent PKA and PKC
Figure 5. FOXL2 binds the conserved element and mutation of the site blocks increased stimulation by FOXL2:C134W. (A) EMSA
analysis of in vitro translated FOXL2:wt (wt) and FOXL2:C134W (m) binding of putative conserved binding site in aromatase PII. 38bp c
32P-ATP end-
labelled probes centered on the putative binding site were used with 3 consecutive thymidine bases changed to 3 guanine bases in the mutant
probe (m) (refer to Fig. 6), N. S.: non-specific antibody, FP: FOXL2 bound to probe, P: unbound probe, s: supershifted band. The experiment was
performed three times graphically analyzed (Fig. S2). (B) Luciferase assays using reporters for the wildtype aromatase promoter (2516) and for the
promoter mutated at the putative FOXL2 binding site (m) in the same manner as the EMSA probe. Assays were performed 48hr following transfection
of COV434 cells as indicated and either treated (grey bars) or untreated (white bars) with combined FSK and PMA. Means of four experiments, error
bars are 6SEM, differences in expression were tested by 1-way ANOVA followed by Tukey’s post-hoc analysis considering all possible comparisons,
indications of significance are a.=p,0.05, b.=p,0.01, c.=p,0.001 and n.=not significant.
doi:10.1371/journal.pone.0014389.g005
Figure 6. Comparison of the identified putative FOXL2 binding site with various relevant sequences. The identified conserved
sequence (highlighted in yellow) was aligned with the FOXL2 binding site in the FSHB promoter described by Corpuz et al. [44] and the consensus
sequences for the forkhead [45], IRS [46] and DMRT [53] elements. Bases mutated in EMSA and luciferase reporter assays (Fig. 5) are
underlined.
doi:10.1371/journal.pone.0014389.g006
FOXL2:C134W and Aromatase
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transcription; however on the StAR promoter, FOXL2 binds
DNA indirectly via SF-1, and here the mutation can not alter
transcription (Fig. 7). Intriguingly, a candidate for the unknown
protein may be another molecule of FOXL2 itself. If FOXL2 were
to form a dimer, this interaction may be altered by the mutation
and affect target transcription. Dimerization of FOXL2 is
supported by recent in silico modeling based on crystal structures
of other forkhead protein family members [22] and by our
observation of a minor band with increased intensity in the
FOXL2:C134W lanes of our EMSA blots (Fig. 5A). However, the
observed band represents only a small portion of the protein and
other scenarios remain equally possible, for example, the mutation
may alter a protein-protein interaction with another member of
the forkhead transcription factor family, perhaps a FOXO protein,
which binds to the DNA element instead of FOXL2. In support of
this idea, the element is a putative IRS as mentioned, and an
analogous regulation of a FOXO protein by further forkhead
family member, FOXG1, was reported to operate on the p21/
Cip1 promoter in glioblastoma cells [58]. Further work is therefore
required before the exact molecular details of the action of
FOXL2 at the identified site are established.
Nevertheless, these studies reveal that aromatase is a target of
FOXL2:C134W and identify the genomic element through which
it operates. The element is of a type known to be bound by FOXO
proteins, and through its conservation, it appears to be of
fundamental importance in the ovary. The translation of these
findings to other genes will illuminate the functional consequence
of FOXL2:C134W in GCT.
Materials and Methods
Cell lines
KGN cells [27] were maintained in DMEM/HamsF12 media
(Invitrogen, Carlsbad, CA; Gibco) supplemented with 10% fetal
bovine serum (FBS), 2mM L-glutamine and penicillin/streptomy-
cin antibiotics (Invitrogen; Gibco) in a 37uC incubator with 5%
CO2. COV434 cells [28,29] were maintained in the same manner
except that the base media was DMEM (Invitrogen; Gibco). FSK
(Sigma-Aldrich, St Louis, MO) and PMA (Sigma-Aldrich) were
used at final concentrations of 25mM and 4nM, respectively.
Molecular biology and expression constructs
The FOXL2 gene was amplified and then sequenced with a
31306l Genetic Analyzer (Life Technologies, Carlsbad, CA;
Applied Biosystems) using primers previously described [7]. The
FOXL2 expression construct was generated by sub-cloning from
the IMAGE consortium clone 6572303 into pcDNA3.1+ with or
without sequence encoding a FLAG tag. Site-directed mutagenesis
of the FOXL2 expression constructs and the aromatase luciferase
reporter was performed with the QuickChange II kit (Agilent
Technologies, Santa Clara, CA; Stratagene) and appropriate
oligonucleotides. The expression construct for SF-1 was a kind gift
from Dr. Ken-ichirou Morohashi and the construct for LRH-1
was previously reported [33].
RT-qPCR
RNA was prepared using the Trizol reagent (Agilent Technol-
ogies; Stratagene) according to the manufacture’s instructions and
cDNA was generated using AMV reverse transcriptase (Promega,
San Luis Obispo, CA) with poly-dT primers. RT-qPCR was
performed on a Rota-Gene RG-3000 (Qiagen, Germantown,
MD; Corbett Life Science) using previously described primer sets
for SF-1 [59], aromatase [60] and FOXL2 [7].
Luciferase assays
Cells were plated at 15% confluence and transiently co-
transfected with constructs of interest and either PII 2516bp-
luciferase [31], a modified version of that construct as described
below, or StAR 21300bp-luciferase [32], using the Fugene 6
reagent (Roche, Basel, Switzerland). Cells were washed and/or
treated with combined FSK and PMA at 24hrs and luciferase
assays were performed at 48hrs using the Dual-Luciferase
Reporter Assay System (Promega) and measured on a Victor 2
plate reader (Perkin Elmer, Waltham, MA; Wallac). Firefly
luciferase signals were compared to Renilla luciferase signals
generated by co-transfection of a Renilla luciferase expression
construct [61].
Co-immunoprecipitation and Western analysis
For Western analysis of expression from the FLAG-tagged
FOXL2 expression constructs, lysates were generated by the
addition of lysis buffer containing 1% Igepal CA-630 (Sigma-
Aldrich), 24hr following transfection. The proteins were separated
on a SDS-PAGE gel and visualized by standard methods using
anti-FLAG antibody (Sigma-Aldrich; M2). For co-immunoprecip-
itation, lysates were generated in the same manner and then mixed
with Anti-FLAG M2 Affinity Gel (Sigma-Aldrich). The beads were
washed three times with 20 volumes of lysis buffer and then boiled
in denaturing sample loading buffer. The remaining proteins were
separated on a SDS-PAGE gel and visualized using commercially
available antibodies for LRH-1 (Abcam, Cambridge, MA;
ab18293) and FLAG (Sigma-Aldrich; M2), and with anti-sera for
SF-1 that was kindly provided by Dr. Ken-ichirou Morohashi.
Densitometry was performed with EZQuantGel (EZQuant, Tel-
aviv, Israel).
Homology analysis
DNA homology analysis was performed via the University of
California Santa Cruz (UCSC) Genome Browser [62] employing
Figure 7. Proposed model for FOXL2:C134W action on the
aromatase and StAR promoters in GCT. FOXL2 stimulates both
aromatase and StAR, but C134W only increases stimulation of
aromatase. Given the sequence of the putative binding site in PII, it is
likely that FOXL2 directly binds the promoter of aromatase at that site,
recruiting an unknown protein(s), and this is altered by the mutation,
whereas on the StAR promoter, FOXL2 acts indirectly, perhaps via SF-1/
LRH-1. However, other explanations are possible (see discussion). F:
FOXL2, S: SF-1/LRH-1.
doi:10.1371/journal.pone.0014389.g007
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aromatase promoter sequence with phyloP genome conservation
data based on 32 placental mammalian genomes [64] and with
Multiz genome alignments based on 46 vertebrate genomes [65].
The phyloP score is displayed in units of 2log p-value of a null
hypothesis of neutral evolution for the given base pair.
Transcription factor recognition site predictions were generated
with MatInspector [66].
EMSA
Probes of the sequences 59-tttcttgggcttccttgttttgacttgtaaccataaat-
39 and 59- tttcttgggcttccttggggtgacttgtaaccataaat-39 (mutant) were
prepared by end labeling annealed oligos with c
32P-ATP using T4
Polynucleotide Kinase (Promega) and purification with Micro-
Spin
TM G-50 Sephadex columns (Amersham Biosciences). EMSA
were performed by incubating the probes with in vitro translation
products generated with the TNT Quick transcription/translation
kit (Promega) either with or without appropriate antibodies. The
complexes were separated on non-denaturing polyacrylamide gels
and visualized by drying and subsequent overnight exposure to
autoradiography Hyperfilm MP at 280C (GE Healthcare).
Densitometry was performed with EZQuantGel (EZQuant, Tel-
aviv, Israel).
Supporting Information
Figure S1. FOXL2:wt and FOXL2:C134W constructs were
expressed equally following transfection. The FOXL2:wt (wt) and
FOXL2:C134W (m) constructs were transiently transfected into
COV434 cells and lysates were prepared 24hr later. The lysates of
three experiments were visualized together on a single Western
blot using anti-FLAG antibody. (A.) Western blot. (B.) Densitom-
etry of bands detected in B. Mean of three experiments, error bars
are 6SEM.
Found at: doi:10.1371/journal.pone.0014389.s001 (0.85 MB TIF)
Figure S2. FOXL2:wt and FOXL2:C134W bound to the
promoter probe and bound less to the mutated probe in a similar
manner. Densitometry of three EMSA blots including the example
shown in Fig. 5A. Mean of three experiments, error bars are
6SEM, m. mutant, wt. wildtype, N. S. non-specific.
Found at: doi:10.1371/journal.pone.0014389.s002 (0.50 MB TIF)
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